My take on CXR3 negatives of substance
1, two drugs in north America are facing pressure, one of which annual sale is 23 m .
2, change of regulation in UK
3, change of sentiment on pharma companiess, especailly for those which have take-over strategy.
The price is down from $100 to 5.
For #3 , well, you can not measure semtiment and qualitfy it
For #2, It may or may not affect the UK sale. Even it dose, it will be later of 2017
From only #1, we can see the revenue down guidance of 14%.
No way CXR cannot pay 144 m BP in q4, now already down from $ 220 m to 199 m because of exchange rate
Strategic review will take a little longer because of the changed situation--UK regaulation and a generic drug competition